MOUNTAIN VIEW, Calif.
, Sept. 30
/PRNewswire/ -- Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona
by the Neuroradiology team of Drs. Juan Macho
and Jordi Blasco
The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first to evaluate Stentriever technology in a European, multicenter, prospective trial. TREVO is designed to assess the ability of the Trevo System to remove the blood clots that cause strokes and to restore blood flow to the brain. Additionally, functional outcomes at 90 days will be collected. Professor Olav Jansen, Head of Interventional Neuroradiology at Universitatsklinikum Schleswig-Holstein, and Professor Nils Wahlgren, Professor of Neurology at Karolinska University Hospital, are co-Principal Investigators of the Study.
Following the treatment of the first patients enrolled into the TREVO Study, Juan Macho, MD, PhD. said, "The Trevo System represents a new treatment option for ischemic stroke patients. It is easy and fast to use and this is essential in the acute stroke setting because a patient's brain is at risk. I have found the Trevo to be remarkably effective."
Maria Sainz, President and CEO of Concentric Medical, commented on the importance of the study, "Treatment of the first patients in the TREVO Study is a key milestone that demonstrates Concentric's continued commitment to advancing acute stroke intervention. The TREVO Study will provide prospective multi-center clinical evidence that will accelerate adoption of this new technology for acute ischemic stroke patients." She added, "European physicians have been pioneers in investigating the clinical possibilities of stentriever technology, so we are excited to conduct our first study with our newest device, Trevo, in Europe."
About Concentric Medical
Concentric Medical is located in Mountain View, California and is the global leader in the development of endovascular devices for revascularizing stroke patients. The company manufactures and markets solutions for ischemic stroke: minimally invasive devices that are delivered into the brain to restore blood flow by removing blood clots that cause ischemic stroke. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies in which over 1,300 patients have been enrolled. For more information about Concentric Medical, please visit www.concentric-medical.com.
About the Trevo System
The Trevo System is an innovative, high-performing, easy-to-use thrombus retrieval system that utilizes Stentriever technology and creates a new generation of retrieval devices to remove clot in ischemic stroke patients. Concentric Medical is the pioneer in developing devices for ischemic stroke intervention. Since 2002, Concentric Medical's devices have been used in thousands of stroke patients worldwide. This experience has been incorporated into the design of the Trevo System to make thrombus removal an easier, faster and more predictable procedure. The new Trevo System combined with the Merci® portfolio of products further strengthens Concentric Medical's position as the global leader in acute ischemic stroke intervention.
About Acute Ischemic Stroke
Stroke is the third leading cause of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain. CE mark for the Merci Retriever was first obtained in 2002. In 2004 the FDA cleared Concentric Medical's Merci Retriever® for use in patients who are ineligible for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device creates a departure from the historic method of caring for stroke patients and offers physicians and patients a long-awaited option for stroke intervention.
SOURCE Concentric Medical, Inc.